Recently, new work focusing on the disruption of BCR/ABL1 by genome-editing nucleases as a therapeutic strategy in CML has revealed the therapeutic potential of the CRISPR system. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.